COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies (COVIDVAC OH)
Multicenter, Observational Study of Anti-Sars-Cov2 Vaccine Efficacy in Patients With Malignant Pathologies Treated in the University Hospitals of AP-HP. Nord
Sponsor: Assistance Publique - Hôpitaux de Paris
Listed as NCT04776005, this observational or N/A phase trial focuses on Cancer, Treatment-Related and Hematologic Malignancy and remains ongoing. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 9 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Jul 2023 — Feb 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Dec 2021 — Jul 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .